+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 60 Pages
  • September 2023
  • GlobalData
  • ID: 4282150
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Glenmark Pharmaceuticals Ltd (Glenmark) focuses on the discovery and development of new chemical entities (NCEs). It develops and markets branded and generic formulations. The company's formulations business encompasses therapeutic areas such as dermatology, respiratory, and oncology. The company also has presence in other therapeutic areas such as diabetes, cardiovascular and oral contraceptives. The company manufactures and supplies active pharmaceutical ingredients (APIs). Glenmark has manufacturing facilities in India, Argentina, the US and Czech Republic. The company markets its products in North America, Japan, Latin America, Europe, India, Middle East North Africa (MENA), Asia and Russia, among others. Glenmark is headquartered in Mumbai, Maharashtra, India.

Glenmark Pharmaceuticals Ltd Key Recent Developments

  • Aug 22023: Glenmark Pharmaceuticals, USA Reaches Antitrust Settlement with DOJ
  • Aug 11023: Glenmark Pharmaceuticals Announces Unaudited Financial Results for the Quarter Ended 30 June 2023
  • May 19023: Glenmark Pharmaceuticals announces audited financial results for the quarter and year ended 31 March, 2023
  • Apr 25023: Glenmark Pharmaceuticals : Industry update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Glenmark Pharmaceuticals Ltd - Key Facts
  • Glenmark Pharmaceuticals Ltd - Key Employees
  • Glenmark Pharmaceuticals Ltd - Key Employee Biographies
  • Glenmark Pharmaceuticals Ltd - Major Products and Services
  • Glenmark Pharmaceuticals Ltd - History
  • Glenmark Pharmaceuticals Ltd - Company Statement
  • Glenmark Pharmaceuticals Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Glenmark Pharmaceuticals Ltd - Business Description
  • Other Break-up: Other Operating Revenue
  • Performance
  • Other Break-up: Sale of Products
  • Performance
  • Other Break-up: Sale of Services
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: India
  • Performance
  • Geographical Segment: Latin America
  • Performance
  • Geographical Segment: North America
  • Performance
  • Key Stats
  • Geographical Segment: Rest of the World (ROW)
  • Performance
  • R&D Overview
  • Glenmark Pharmaceuticals Ltd - Corporate Strategy
  • Glenmark Pharmaceuticals Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Glenmark Pharmaceuticals Ltd - Strengths
  • Glenmark Pharmaceuticals Ltd - Weaknesses
  • Glenmark Pharmaceuticals Ltd - Opportunities
  • Glenmark Pharmaceuticals Ltd - Threats
  • Glenmark Pharmaceuticals Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Glenmark Pharmaceuticals Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 22, 2023: Glenmark Pharmaceuticals, USA Reaches Antitrust Settlement with DOJ
  • Aug 11, 2023: Glenmark Pharmaceuticals Announces Unaudited Financial Results for the Quarter Ended 30 June 2023
  • May 19, 2023: Glenmark Pharmaceuticals announces audited financial results for the quarter and year ended 31 March, 2023
  • Apr 25, 2023: Glenmark Pharmaceuticals : Industry update
  • Feb 10, 2023: Glenmark Pharma Announces Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2022
  • Dec 06, 2022: WARNING LETTER : Glenmark Pharmaceuticals
  • Nov 14, 2022: Glenmark Pharma reports revenue growth of 7.2% YoY and EBITDA margin of 18.4% for Q2 FY 2022-23
  • Nov 11, 2022: Glenmark Pharmaceuticals announces Unaudited Financial Results (Standalone And Consolidated) For The Second Quarter And Half Year Ended September 30, 2022
  • Jul 01, 2022: U.S. FDA inspection at the company's Aurangabad, India facility
  • May 29, 2022: Glenmark Pharma reports revenue growth of 5.6% YoY Q4; 12.4% for the full year FY 2021-22
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Glenmark Pharmaceuticals Ltd, Key Facts
  • Glenmark Pharmaceuticals Ltd, Key Employees
  • Glenmark Pharmaceuticals Ltd, Key Employee Biographies
  • Glenmark Pharmaceuticals Ltd, Major Products and Services
  • Glenmark Pharmaceuticals Ltd, History
  • Glenmark Pharmaceuticals Ltd, Other Locations
  • Glenmark Pharmaceuticals Ltd, Subsidiaries
  • Glenmark Pharmaceuticals Ltd, Key Competitors
  • Glenmark Pharmaceuticals Ltd, Ratios based on current share price
  • Glenmark Pharmaceuticals Ltd, Annual Ratios
  • Glenmark Pharmaceuticals Ltd, Interim Ratios
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Glenmark Pharmaceuticals Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Glenmark Pharmaceuticals Ltd, Performance Chart (2019 - 2023)
  • Glenmark Pharmaceuticals Ltd, Ratio Charts
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Dr. Reddy's Laboratories Ltd
  • Viatris Inc
  • Torrent Pharmaceuticals Ltd
  • ANI Pharmaceuticals Inc
  • Alkem Laboratories Ltd
  • Teva Pharmaceutical Industries Ltd
  • Aurobindo Pharma Ltd
  • Pfizer Ltd India
  • Sun Pharmaceutical Industries Ltd
  • Emcure Pharmaceuticals Ltd
  • Divi's Laboratories Ltd
  • ANI Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Ltd India
  • Dr. Reddy's Laboratories Ltd
  • Viatris Inc
  • Mylan Laboratories Ltd
  • Emcure Pharmaceuticals Ltd
  • Aurobindo Pharma Ltd
  • Sun Pharmaceutical Industries Ltd
  • Divi's Laboratories Ltd